Cargando…

Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder

BACKGROUND: Recent clinical trials indicate that pharmacogenetic-guided treatment of major depressive disorder (MDD) results in higher treatment response rates by genetically matching patients to medications and avoiding a trial-and-error process. OBJECTIVE: To evaluate the cost-effectiveness of a p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Groessl, Erik J., Tally, Steven R., Hillery, Naomi, Maciel, Alejandra, Garces, Jorge A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397625/ https://www.ncbi.nlm.nih.gov/pubmed/30058980 http://dx.doi.org/10.18553/jmcp.2018.24.8.726

Ejemplares similares

Cost-Effectiveness of Humidified High-Flow Therapy (HHFT) for COPD Patients on Long-Term Oxygen Therapy
por: Groessl, Erik J, et al.
Publicado: (2023)

Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings
por: Maciel, Alejandra, et al.
Publicado: (2018)

Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix(®)) to Guide Treatment of Patients with Depression and/or Anxiety
por: Najafzadeh, Mehdi, et al.
Publicado: (2017)

Clinical Phenotypes Characterization in Pharmacogenetics Testing Trials for Major Depressive Disorder Treatment
por: Minelli, A.
Publicado: (2022)

The role of pharmacogenetics in the treatment of major depressive disorder: a critical review
por: Barlati, Stefano, et al.
Publicado: (2023)

Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
por: Verbelen, M, et al.
Publicado: (2017)

Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial
por: Pérez, Víctor, et al.
Publicado: (2017)

Cost analysis of rapid diagnostics for drug-resistant tuberculosis
por: Groessl, Erik J., et al.
Publicado: (2018)

The utility of pharmacogenetic testing to support the treatment of bipolar disorder
por: Ielmini, Marta, et al.
Publicado: (2018)

A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
por: Lee, Kyung Ho, et al.
Publicado: (2021)

A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants
por: Kanders, Sofia H., et al.
Publicado: (2019)

Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective
por: Carta, Andrea, et al.
Publicado: (2022)

Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review
por: Morris, Sarah A., et al.
Publicado: (2022)

Pharmacogenetics to Personalize Dosing of Tricyclic Antidepressants in Major Depressive Disorder: A Randomized Clinical Trial (PITA study)
por: Ter Hark, S., et al.
Publicado: (2023)

Effectiveness of a Pharmacogenetic Tool at Improving Treatment Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Clinical Studies
por: Vilches, Silvia, et al.
Publicado: (2019)

Case report: application of pharmacogenetics in the personalized treatment of an elderly patient with a major depressive episode
por: Pjevac, Milica, et al.
Publicado: (2023)

Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods
por: Asadov, Chingiz, et al.
Publicado: (2017)

EXPERIENCE OF PHARMACOGENETIC TESTING IN THE TREATMENT OF ANTIPSYCHOTICS
por: Kaydan, M., et al.
Publicado: (2023)

Ten Years of Experience Support Pharmacogenetic Testing to Guide Individualized Drug Therapy
por: Peña-Martín, María Celsa, et al.
Publicado: (2022)

Pharmacogenetics and Depression: A Critical Perspective
por: Corponi, Filippo, et al.
Publicado: (2019)

Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report
por: Singh, Ajeet B.
Publicado: (2015)

Pharmacogenetic testing in the Veterans Health Administration: Policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee
por: Vassy, Jason L., et al.
Publicado: (2018)

Pharmacogenetics of asthma in children
por: Kondo, Naomi, et al.
Publicado: (2010)

Cost effectiveness of pharmacogenetic-guided clozapine administration based on risk of HLA variants in Japan and the UK
por: Ninomiya, Kohei, et al.
Publicado: (2021)

Pharmacogenetics in Primary Headache Disorders
por: Belyaeva, Irina I., et al.
Publicado: (2022)

Pharmacogenetic testing among patients with depression in a US managed care population
por: Anderson, Heather D., et al.
Publicado: (2022)

Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany
por: Plöthner, Marika, et al.
Publicado: (2016)

Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings
por: Smith, D. Max, et al.
Publicado: (2020)

Clinical utility of pharmacogenetic testing in children and adolescents with severe mental disorders
por: Blasco-Fontecilla, Hilario
Publicado: (2018)

LITHIUM IN THE TREATMENT OF BIPOLAR DISORDER: PHARMACOLOGY AND PHARMACOGENETICS
por: Alda, Martin
Publicado: (2015)

Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy
por: Mencacci, Claudio, et al.
Publicado: (2013)

Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy
por: Tuteja, Sony, et al.
Publicado: (2021)

The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder
por: Sobocki, P, et al.
Publicado: (2008)

Primary care and mental health providers’ perceptions of implementation of pharmacogenetics testing for depression prescribing
por: Vest, Bonnie M., et al.
Publicado: (2020)

The Potential Utility of Pharmacogenetic Testing in Psychiatry
por: Gardner, Kathryn R., et al.
Publicado: (2014)

Variant Interpretation in Current Pharmacogenetic Testing
por: Luvsantseren, Sally, et al.
Publicado: (2020)

The Utility of Pharmacogenetics Testing in Psychiatric Populations
por: Jürgens, Gesche
Publicado: (2021)

Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial
por: Strawn, Jeffrey R., et al.
Publicado: (2021)

The use of pharmacogenetic testing in patients with schizophrenia or bipolar disorder: A systematic review
por: Routhieaux, Melanie, et al.
Publicado: (2018)

S222. CLINICAL UTILITY OF PHARMACOGENETIC TESTING IN SCHIZOPHRENIA TREATMENT
por: Mueller, Daniel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ov92iv4gf40qlgkielqcojl63i